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Background: Drug-eluting stents with biodegradable polymers have been developed
to address the risk of very late adverse events. The purpose of this analysis was to
compare safety and efﬁcacy of the biodegradable polymer-coated biolimus-eluting
stent (Nobori; BES) to the durable polymer-coated everolimus-eluting stent
(Xience or Promus; EES) in patients treated with primary percutaneous coronary
intervention (PCI) for ST-elevating myocardial infarction (STEMI).
Methods: The COMPARE II study is an open-label, prospective, randomized, non-
inferiority, all-comers trial undertaken at 12 sites across Europe currently at 3-year
follow-up. Patients were randomly allocated (2:1) to receive either BES or EES. We
performed a sub-analysis of patients treatedwith primary PCI. The pre-speciﬁed endpoint
major adverse cardiovascular event (MACE) was a composite of the safety endpoints
cardiac death or non-fatal myocardial infarction (MI) and the efﬁcacy endpoint clinically
indicated target vessel revascularization (CI-TVR), analyzed by intention to treat.
Results: Of the 2707 study patients, 569 patients (21%) underwent primary PCI for
STEMI with 372 treated with BES and 197 with EES. The 3-year outcomes for pa-
tients undergoing primary PCI with BES or EES are tabulated.Events at 3 years
EES
(n¼197)
BES
(n¼372)
Relative Risk
[95% CI] p-value
All-cause Death 3.6% (7) 4.3% (16) 1.21 [0.51-
2.89]
0.67
Cardiac Death 3.0% (6) 2.7% (10) 0.88 [0.33-
2.39]
0.80
Myocardial Infarction 3.6% (7) 3.8% (14) 1.06 [0.43-
2.58]
0.90
Target Vessel
Revascularization (Any)
2.0% (4) 6.2% (23) 3.05 [1.07-
8.68]
0.03
Target Vessel
Revascularization (CI)
2.0% (4) 4.6% (17) 2.25 [0.77-
6.60]
0.13
Target Lesion
Revascularization (Any)
1.5% (3) 5.1% (19) 3.35 [1.00-
11.19]
0.03
Target Lesion
Revascularization (CI)
1.5% (3) 4.0% (15) 2.65 [0.77-
9.03]
0.10
Def./Prob. Stent Thrombosis 1.5% (3) 1.9% (7) 1.24 [0.32-
4.73]
0.76
Deﬁnite Stent Thrombosis 0.5% (1) 1.9% (7) 3.71 [0.46-
29.91]
0.19
Very Late Def./Prob. Stent
Thrombosis
1.0% (2) 1.1% (4) 1.06 [0.20-
5.73]
0.95
MACE 7.1% (14) 8.3% (31) 1.17 [0.64-
2.15]
0.61Conclusions: At 3-year follow-up the biodegradable polymer-coated BES displayed
similar incidence of the pre-speciﬁed endpoint MACE compared to the durable
polymer-coated EES in patients treated with primary PCI, yet showed higher rates of
target vessel and target lesion revascularizations.JACC Vol 64/11/Suppl B j September 13–17, 2014 j TCT Abstracts/AcTCT-16
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Background: In the setting of successfully reperfused acute ST elevation
myocardial infarction (STEMI) we hypothesized that thermodilution-derived index of
microcirculatory resistance (IMR) measured after primary percutaneous coronary inter-
vention (PCI), may be useful to predict LV remodeling 6months after successful coronary
reperfusion.
Methods: We prospectively enrolled 89 patients (age 529 years; 86% male)
with anterior STEMI. All patients were successfully treated by PCI with establishment
of Thrombolysis In Myocardial Infarction (TIMI) 3 ﬂow after PCI. The thermodilu-
tion-derived index of microcirculatory resistance (IMR) was thereafter measured by
using the pressure-temperature sensor-tipped coronary wire at the left anterior
descending artery (LAD). Angiographic parameters such as TIMI ﬂow and blush
grade were also recorded. Baseline comprehensive cardiovascular magnetic resonance
(CMR) was performed before discharge and at 6 months follow-up. Comprehensive
CMR included cine, T2-weighted, and late gadolinium enhancement (LGE) imaging.
Infarct size (IS) and microvascular obstruction (MVO) were correlated to IMR mea-
surements. LV remodelling was deﬁned as a >20% increase of LV volume at 6
months.
Results: LV remodelling was observed in 34.8% of the patients (31/89). TIMI ﬂow
and blush grade after PCI was not different between patients with and without
LV remodeling (3 for TIMI ﬂow and 2 for Blush grade respectively, p ¼ 0.952).
IMR level markedly differed between patients with and without LV remodeling (73,95
vs. 27,23 p¼0,0293). After multivariate analysis IMR>40 was the strongest angio-
graphic parameter to predict LV remodeling (OR15 (1,030-218,4), p¼0,03).Regarding
CMR, patients with LV remodeling had lower LVEF (43% vs. 48%; p ¼ 0.01), larger
infarct size (IS) (51 mg vs 32 mg; p ¼ 0.002) and greater microvascular obstruction
(MVO) extent (4.5seg vs. 2seg; p ¼ 0.03) when compared to patients with no LV
remodeling.
Conclusions: IMR assessed by coronary angiogram after successful PCI in the setting
of acute STEMI is a strong predictive factor of LV remodeling 6 months after suc-
cessful reperfused AMI.
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Background: There is conﬂicting evidence as to whether direct stenting (DS) is su-
perior to balloon angioplasty with subsequent stenting (conventional stenting, CS) in
patients presenting with ST-elevation myocardial infarction (STEMI). This study
aimed at comparing DS and CS in STEMI using a systematic review and meta-
analysis of published evidence.
Methods: We searched EMBASE, MEDLINE and CENTRAL, from inception of
each database to April 2014. The primary endpoint was mortality. Secondary end-
points included major adverse cardiac events (MACEs), ST-segment resolution on
ECG, and angiographic outcomes.
Results: A total of 9,331 patients enrolled in 12 studies (3 randomized controlled
trials, RCTs; 9 non-randomized studies, NRSs) were included. DS was associated with
lower mortality compared to CS (OR 0.55; 95% CI: 0.33 to 0.94; p¼0.03) in NRSs,
and overall (OR 0.56; 95% CI: 0.37 to 0.86; p¼0.008), as shown in the Figure.
Mortality was non-signiﬁcantly reduced in RCTs (OR 0.56; 95% CI: 0.26 to 1.23;
p¼0.15). DS was also associated with lower MACE rate (OR 0.69; 95% CI 0.54 to
0.87; p¼0.002) in NRSs, but not in RCTs (OR 0.82; 95% CI: 0.38 to 1.77; p¼0.62).
ST-segment resolution, no reﬂow, ﬁnal thrombolysis in myocardial infarction (TIMI)
ﬂow grade and ﬁnal TIMI myocardial perfusion or blush grade were signiﬁcantly
better with DS in NRSs, and non-signiﬁcantly better in RCTs.ute Myocardial Infarction B5
SATURDAY, SEPTEMBER 13, 2014, 5:00 PM–7:00 PM www.jacctctabstracts2014.comConclusions: The available evidence suggests that DS in STEMI is associated with better
clinical and procedural outcomes, in particular lower mortality, as compared with CS.
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Background: Decreased LVEF at presentation during STEMI has been established as
a predictor of morbidity and mortality. Many patients have improvement in LVEF
over time due to recovery of hibernating or stunned myocardium. Little data exists on
the clinical and angiographic predictors of improvement in LVEF after stenting.
Methods: In HORIZONS-AMI, 3,602 patients presenting with STEMI at 123 sites
were randomized to heparin + a glycoprotein IIb/IIIa inhibitor (H+GPI) vs. bivalir-
udin, and to paclitaxel-eluting stents vs. bare metal stents. Clinical follow-up was
performed for three years, including routine angiographic follow-up at 13 months in a
pre-speciﬁed substudy.
Results: Baseline and 13-month follow-up LVEF measurements were available in 656
patients, comprising the current study cohort. The median change [interquartile range]
in LVEF from baseline to 13 months was +2.4% [-5.85%, 11.80%]. During follow-up
LVEF rose or remained the same in 379 (57.8%) patients (median D +9.8% [4.30%,
16.40%]), and fell in 277 (42.2%) patients (median D -7.0% [-11.80%, -3.60%]). By
multivariable analysis, independent predictors of improvement in LVEF were female
sex (p¼0.002) and TIMI 3 ﬂow after PCI (p¼0.03), while longer lesion length
(p¼0.04), greater peak CKMB (p< 0.0001) and higher baseline LVEF (p< 0.0001)
predicted LVEF decrease (Table). Of note, use of drug-eluting vs. bare metal stents,
bivalirudin vs. H+GPI, symptom-to-balloon time, and discharge use of beta-blockers
or ACEI/ARBs were not signiﬁcant predictors of LVEF improvement.Table. Multivariable Correlates of LVEF Improvement from Baseline to
13 Months
Multivariable Correlates Odds Ratio [95% CI] (adjusted) P Value
Female sex 2.08 [1.3, 3.33] 0.002
Baseline LVEF 0.90 [0.88, 0.91] <0.0001
Peak CKMB 1.00 [1.00, 1.00] <0.0001
TIMI 3 ﬂow post-PCI 1.96 [1.06, 3.62] 0.03
Total lesion length 0.98 [0.97, 1.00] 0.04
B6 JACC Vol 64/11/Suppl B jConclusions: While LVEF improves during follow-up in more than half of patients
after primary PCI, a signiﬁcant proportion have worsening LV function over time.
Further approaches are required to improve myocardial recovery after mechanical
reperfusion therapy in STEMI.
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Background: Primary percutaneous coronary intervention (PCI) is the preferred
method of reperfusion in ST-segment elevation myocardial infarction (STEMI).
Target vessel revascularization (TVR) due to restenosis or disease progression may
compromise the beneﬁts of primary PCI. The predictors and impact of TVR after
STEMI are not well understood.
Methods: In HORIZONS AMI 3,602 patients with STEMI were randomized to
bivalirudin vs. heparin and a glycoprotein IIb/IIIa inhibitor; stents were implanted in
3,202 patients. Ischemia-driven TVR of the infarct-related artery (IRA) required
recurrent angina and/or signs of ischemia and 50% diameter restenosis, or 70%
diameter stenosis even in the absence of ischemia.
Results: TVR occurred in 219 (6.9%) patients at 1 year, 392 (12.9%) at 2 years, and 437
(14.4%) at 3 years. Repeat PCI was performed in 410 (93.0%) patients and CABG in 48
(11.4%, not mutually exclusive). TVRwas ischemia-driven in 418 patients (95.7%). TVR
was due to restenosis in 343 patients (80.2%) and disease progression in 94 (19.8%). Pa-
tients with vs. without TVR had similar rates of death (6.6% vs. 6.3%, P¼0.87), but
markedly higher rates ofMI (35.3% vs. 2.7%, P< 0.0001) and non-CABGmajor bleeding
(13.8%vs. 7.8%, P< 0.001). Of the 151MI events in the TVR group, 29 (19.2%) occurred
before (average 35 days) TVR, 13 (8.6%) occurred after (average 166 days) TVR, and the
rest (72.2%) occurred on same day asTVR.Half of theMIs beforeTVRoccurredwithin 48
hours of it, suggesting that TVRwas the result of theMI. Target lesion deﬁnite SToccurred
in 29.2% of TVR patients and in 0.4% of non-TVR group, P< 0.0001. Only one third of
them occurred beyond 1 year. Independent predictors of TVR were more extensive CAD
(HR¼1.18 per diseased vessel, P¼0.006), smaller vessel size (HR¼1.37 per mm,
P¼0.006), longer lesion length (HR¼1.01 per mm, P¼0.003), scheduled angiographic
follow-up (HR¼1.41, P¼0.001) and treatment with bare metal rather than drug-eluting
stents (HR¼1.59, P< 0.0001).
Conclusions: TVR occurs in 1 of every 7 STEMI patients within 3 years after primary
PCI, is usually due to restenosis rather than disease progression, and is strongly related
to adverse outcomes (but not death).
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Background: Myocardial perfusion is impaired in up to 40% of patients after primary
PCI (pPCI) for ST-segment elevation myocardial infarction (STEMI), which is asso-
ciated with adverse clinical outcomes. Pressure-controlled intermittent coronary sinus
occlusion (PICSO) aims to improvemicrovascular perfusion after pPCI by intermittently
increasing the pressure in the cardiac venous outﬂow tract by means of a balloon-tipped
catheter in the coronary sinus.We evaluated the safety and feasibility of adjuvant PICSO
after pPCI for STEMI, and its effects on infarct size and myocardial function.
Methods: We enrolled 30 patients after successful pPCI for anterior STEMI. PICSO
for 90 minutes was attempted, and the quantity of PICSO therapy provided throughout
the procedure was documented (mm Hg of coronary sinus pressure modulation).
Infarct size and myocardial function were assessed by cardiovascular magnetic
resonance (CMR) at 2-5 days and 4-months post-pPCI, and the results were compared
with a matched historical control group.
Results: PICSO could be initiated in 19 patients (63%). Major adverse safety events
occurred in 1 patient (3%). When PICSO could be initiated, median PICSO duration was
88.8 min (Q1–Q3: 72.0–89.6 min), and could be maintained for 90(2) minutes in 12
patients (40%). However, the quantity of PICSO therapy varied from 15 to 2735 mmHgSeptember 13–17, 2014 j TCT Abstracts/Acute Myocardial Infarction
